-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $34

Benzinga·11/10/2026 10:11:20
Listen to the news
Stifel analyst Paul Matteis initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $34.